Kinase Inhibitor Screening in Myeloid Malignancies

Publication date: Available online 19 May 2017
Source:Hematology/Oncology Clinics of North America
Author(s): Jeffrey W. Tyner

Teaser

Kinase pathways are primary effectors of many targeted therapy approaches for cancer. Kinase pathways can be dysregulated by mechanisms far more diverse than chromosomal rearrangements or point mutations, which drove the initial application of kinase inhibitors to cancer. Functional screening with kinase inhibitors is one tool by which we can understand the diversity of target kinases and candidate drugs for patients before fully understanding the mechanistic rationale for kinase pathway dysregulation. By combining functional screening with genomic data, it is also possible to accelerate understanding of these mechanistic underpinnings.


http://ift.tt/2rCrk9Y